Nov 9
Current report
8-K
Events of Nov 6
Director or officer change, or executive pay
AI summary on its way
MYGN · Myriad Genetics Inc
$5.66
-0.02 (-0.35%)
At close · Nov 13
Return incl. dividend (before tax)
Market Cap
$541.38M
Shares
95.65M
Volume · Nov 13
1.05M
Avg daily vol (3M)
2.3M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.66
Open$5.71
Day$5.51–5.71
52W close$2.86–7.91
Avg vol 30d2.7M
Short int8.4M · 8.8% of shares · 2.0d
Short vol35%
Last earningsNov 4, 2026
DataJan 2020–Nov 2026
Filing10-Q · Nov 6
Up next
Feb 22, 2027
Est · unconfirmed
· in 14 wks
Latest documents
2026
Nov 6
Quarterly report
10-Q
FY2026 Q3, ended Sep 30
Prenatal asset sale brings $210 million as revenue falls
Myriad Genetics agreed to sell Prenatal Health assets to Laboratory Corporation of America for $210 million plus inventory value; closing is expected by early 2027. Revenue fell $3.0 million to $202.7 million for the three months ended September 30, 2026.
Revenue $202.7M
▼ 1.5%
Net loss $43.9M
Diluted EPS -$0.46
Nov 5
Current report
8-K
Events of Nov 2
Unauthorized IT access detected; operations largely restored
On November 2, 2026, Myriad Genetics, Inc. detected unauthorized IT access, temporarily suspended testing operations and order management systems, and began investigating whether patient records were accessed. Most systems returned to normal operations.
Nov 4
Earnings call
Prenatal business sale announced; 2026 revenue midpoint raised to $785 million
Myriad Genetics reported Q3 revenue of $202.7 million and raised 2026 guidance midpoint to $785 million from $780 million, mainly on improved revenue per test. It agreed to sell its prenatal health business to LabCorp for $210 million plus inventory.
Nov 4
Current report
8-K
Prenatal Health sale set for $210 million; guidance midpoint raised
Myriad Genetics entered a definitive agreement to sell the Prenatal Health business to Labcorp for $210 million in cash, plus related inventory value. Third quarter 2026 revenue was $202.7 million, and the company raised the midpoint of full-year 2026 revenue guidance.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$803.60M
Trailing 12 months
Net income (TTM)
−$129.10M
Trailing 12 months
Revenue growth YoY
-1.5%
Year over year
Operating margin
-14.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$14.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.8%
Year over year · more shares
Price change (1Y)
-10.9%
Trailing year
Short interest
8.8%
Latest settlement · 2.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 19.3 · elevated
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+23%
above
Price vs 50-day avg
+19%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
55%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+42%
trailing
6-month return
+47%
trailing
YTD return
−8%
this year
Relative strength
+47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
165 of 199 funds reported for Sep 30 · net +1.7M sh shares · +25 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.82% of shares out · ▼ -9.0% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
75%
contracting
EPS growth
−180%
Y/Y
Buyback
$110.7M
remaining
Balance sheet
$29.7M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 4, 2026
Total revenue guidance
· 2026
Lowered
$770M – $790M
May 5, 2026
$860M – $880M
changed to
Aug 4, 2026
$770M – $790M
prior FY $824.5M
midpoint −5.4% Y/Y
Gross margin
· 2026
66% – 67%
Previous outlook
earlier release
· from the 8-K filed Jul 30, 2026
Still-open targets the latest release did not restate under the same label.
Adjusted Gross Margin %
· full-year 2026
66% – 67%
Prior guidance
period ended
· from the 8-K filed Feb 23, 2026
Revenue
· Q1'26
$200M – $203M
Revenue growth
· Q1'26
2% – 4%
Guided vs delivered
· last 7 settled
Revenue
Q1'26
guided $200M – $203M
$200.4M
In line
Revenue
FY 2024
guided $820M – $840M
$837.6M
In line
GAAP EPS
FY 2023
guided $-3.15 – $-3.07
$-3.18
Miss −2.3%
Revenue
FY 2023
guided $730M – $750M
$753.2M
Beat +1.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+23%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
55%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
Golden cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
165 of 199 funds reported for Sep 30 · net +1.7M sh shares · +25 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.82% of shares out · ▼ -9.0% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $6 · 55%
Range high $8
vs 200-day avg +23%
vs 50-day avg +19%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$21.4M | Six months ended June 30 | — |
| Adjusted Free Cash Flow non-GAAP | -$30.8M | Six months ended June 30 | — |
| Adjusted Income (Loss) Per Share non-GAAP | -$0.34 | Six months ended June 30 | — |
| Adjusted Net Income (Loss) non-GAAP | -$31.6M | Six months ended June 30 | — |
| Adjusted Operating Cash Flow non-GAAP | -$21.1M | Six months ended June 30 | — |
| Adjusted operating cash outflow non-GAAP | $7.7M | Q2 2026 | — |
| Adjusted operating expenses non-GAAP | $150.5M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating Expenses 165.9M
-6.4M Acquisition - amortization of intangible assets
+0M Goodwill and long-lived asset impairment
-6.7M Equity compensation
+0M Real estate optimization
-2.3M Strategic realignment
+0M Other adjustments
= Adjusted Operating Expenses 150.5M
|
|||
| Cancer Care Continuum volume | 95K | Q2 2026 | — |
| Cash flow used in operations | $8.3M | Q2 2026 | — |
| Mental Health volume | 140K | Q2 2026 | — |
| Prenatal Health volume | 144K | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MYGN
this stock
Myriad Genetics Inc
|
$541.38M | -8.0% | -7.1% | — | 8.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$259.44B | +20.8% | +14.5% | 36.9 | 1.3% |
|
DHR
Danaher Corp
|
$163.94B | +1.8% | +8.5% | 38.1 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.48B | +4.1% | +10.4% | 47.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.04B | +27.8% | +6.4% | 34.2 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MYGN | -4.4% | +42.2% | +47.0% | -10.9% | -8.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -7.0% | +43.4% | +46.5% | -10.7% | -18.6% |
Capital returns
Buyback program
· as of Sep 30, 2023
Authorized
$200.00M
Spent (derived)
$89.30M
Remaining
$110.70M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
899923
CUSIP
62855J104
13F (30d)
136 filings
121 filers
Visit website
Investor relations